Recent advances in the discovery and delivery of vaccine adjuvants.
about
The anti-vaccination movement and resistance to allergen-immunotherapy: a guide for clinical allergistsChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesRecent advances in oral vaccine development: yeast-derived β-glucan particlesInflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacyAdjuvants for peptide-based cancer vaccinesThe challenge of emerging and re-emerging infectious diseasesUniversal influenza vaccines, a dream to be realized soon.Nasal vaccine innovation.Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.Complete Freund's adjuvant induces experimental autoimmune myocarditis by enhancing IL-6 production during initiation of the immune responseDelivery of foreign antigens by engineered outer membrane vesicle vaccines.Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccinesIn situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in miceWomen and autoimmune diseases.Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity.A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivoTricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development.Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensDeveloping a vaccine against multiple psychoactive targets: a case study of heroin.Ex Vivo and In Vitro Studies on the Cytotoxicity and Immunomodulative Properties of Poly(2-isopropenyl-2-oxazoline) as a New Type of Biomedical Polymer.Targeting the innate immune response with improved vaccine adjuvants.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyIntranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice.Noninvasive delivery technologies: respiratory delivery of vaccines.The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccineAntigen kinetics determines immune reactivity.Making sense of inflammation, epigenetics, and memory CD8+ T-cell differentiation in the context of infection.Achieving directed immunostimulating complexes incorporation.The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cellsImmunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii.Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.Ginseng, the 'Immunity Boost': The Effects of Panax ginseng on Immune System.The science of adjuvants.ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.Design opportunities for actively targeted nanoparticle vaccines.
P2860
Q24595355-DC2FC0B6-7B05-43C2-9E81-7562600E61CDQ26783488-FBC4A7F8-0536-4EE4-B1A8-7D06CE0DE092Q27001699-7E76E53F-4FAF-47E0-8355-28F5AE082FB0Q27488746-A153C123-DE77-4C39-9EFD-52D99D6CEF9EQ28072236-55E01ECA-CE63-4578-81BD-DFB01259CFFEQ29617354-0322E671-023C-4DDA-BED0-978C96A78375Q30361950-8716CA6E-54B6-4EF3-865F-EE9945C0E8A8Q30395810-D3890B1E-BCFF-444D-9890-988AA04F9C1AQ30397437-314F230B-0E73-4600-A462-A7CCCF6AC3E2Q33451335-71CB4CF8-D5BC-45A7-B1C8-C394CFC166ACQ33638740-6B5D8BFF-10D8-407E-B446-F0399162C93DQ33733590-4B321BD7-4CA0-47D1-8109-43DB19172195Q33834852-57EC718F-74A6-47C4-95F6-F1BD69C7A5F4Q34034287-44D43997-2BA4-4B31-B74E-288E02054F03Q34138616-D8B204F7-86E8-483A-B3B3-F602ED85D1F3Q34330250-BF4164AC-DF4F-47D7-817C-8309F3A977C1Q34369064-488C72C6-A491-467C-8984-1A724EEF21ADQ34546201-239FE89B-AB06-4CE1-AF96-A0BCB5045F47Q34717036-F560BE89-4093-40C8-BFAD-2BE4E46BC6D4Q35005484-6FF73CF9-CFAF-43C5-B17E-1C889ED7D070Q35272875-F01C4B15-C715-451B-8D62-B24361926184Q35812875-BC5D95B0-CBFC-42D2-8805-FE4C829F8F24Q35892296-C52A5E7B-7325-4553-87D0-7030B1CDFA30Q36010045-69337F8D-8E72-4D26-BC17-7F204164702EQ36090194-E3C33D7E-3CE6-4916-A894-9779F6C1797BQ36116250-3B1AFCE1-F957-4825-A4F9-03C83E763A3AQ36156444-34D92137-DAF4-45E4-A4D6-99EA3856F978Q36349694-DC2A5B19-4BD4-4998-A397-12D04D7DB5FCQ36398927-014EA42A-D8DC-4739-B7CF-83C9AFF75779Q36484748-1B0CE49E-5EE1-4948-9901-68819A907BFFQ36516144-66F5B230-3B90-4FA1-97C0-7FCAC1FD466AQ36528995-01560BE2-27D6-408E-8EA2-748DDBF57DE8Q36530236-B47A1552-5785-4913-8264-E01EAC01CD61Q36553255-1069A4D6-67E8-45E2-A793-5333C1925758Q36555685-1D1A0B4A-27C3-44CD-AC77-5F8E58DEC967Q36844890-F35FAEF7-C895-49C8-AE64-17E535EF2E1DQ36861216-E703C65C-C09D-422E-97AB-8F5ECC9C3B21Q36968250-1B58BF47-BFCB-4004-8F9C-76E1FF2FEBF0Q36968280-90B35AFA-7BB9-4F6A-AF02-C73D33A31567Q37062606-6B657B21-29AE-4B29-B07C-329E2E54F3D5
P2860
Recent advances in the discovery and delivery of vaccine adjuvants.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Recent advances in the discovery and delivery of vaccine adjuvants.
@ast
Recent advances in the discovery and delivery of vaccine adjuvants.
@en
type
label
Recent advances in the discovery and delivery of vaccine adjuvants.
@ast
Recent advances in the discovery and delivery of vaccine adjuvants.
@en
prefLabel
Recent advances in the discovery and delivery of vaccine adjuvants.
@ast
Recent advances in the discovery and delivery of vaccine adjuvants.
@en
P356
P1476
Recent advances in the discovery and delivery of vaccine adjuvants.
@en
P2093
Derek T O'Hagan
Nicholas M Valiante
P2888
P304
P356
10.1038/NRD1176
P577
2003-09-01T00:00:00Z
P6179
1029167176